JP2010518089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518089A5 JP2010518089A5 JP2009549128A JP2009549128A JP2010518089A5 JP 2010518089 A5 JP2010518089 A5 JP 2010518089A5 JP 2009549128 A JP2009549128 A JP 2009549128A JP 2009549128 A JP2009549128 A JP 2009549128A JP 2010518089 A5 JP2010518089 A5 JP 2010518089A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- picoplatin
- core
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006186 oral dosage form Substances 0.000 claims description 98
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 90
- 229950005566 picoplatin Drugs 0.000 claims description 90
- 239000011248 coating agent Substances 0.000 claims description 62
- 238000000576 coating method Methods 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 48
- 150000001720 carbohydrates Chemical class 0.000 claims description 28
- 235000014633 carbohydrates Nutrition 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 28
- 229920002678 cellulose Polymers 0.000 claims description 26
- 239000001913 cellulose Substances 0.000 claims description 26
- 235000010980 cellulose Nutrition 0.000 claims description 26
- 239000000314 lubricant Substances 0.000 claims description 26
- 239000000945 filler Substances 0.000 claims description 24
- 239000002270 dispersing agent Substances 0.000 claims description 22
- 239000002552 dosage form Substances 0.000 claims description 21
- 239000011859 microparticle Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 16
- 229910052751 metal Inorganic materials 0.000 claims description 14
- 239000002184 metal Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 239000013618 particulate matter Substances 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 8
- -1 alkaline earth metal salt Chemical class 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- 229920003086 cellulose ether Polymers 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000010419 fine particle Substances 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 238000010902 jet-milling Methods 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000002518 antifoaming agent Substances 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000007931 coated granule Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 230000008901 benefit Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88917107P | 2007-02-09 | 2007-02-09 | |
| US88968107P | 2007-02-13 | 2007-02-13 | |
| PCT/US2008/001752 WO2008097661A1 (en) | 2007-02-09 | 2008-02-08 | Stabilized picoplatin oral dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518089A JP2010518089A (ja) | 2010-05-27 |
| JP2010518089A5 true JP2010518089A5 (enExample) | 2012-04-12 |
Family
ID=39682046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549128A Pending JP2010518089A (ja) | 2007-02-09 | 2008-02-08 | 安定化されたピコプラチンの経口投与剤型 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2114418A4 (enExample) |
| JP (1) | JP2010518089A (enExample) |
| KR (1) | KR20090109129A (enExample) |
| CN (2) | CN104288119A (enExample) |
| AU (1) | AU2008214202A1 (enExample) |
| BR (1) | BRPI0806418A2 (enExample) |
| CA (1) | CA2677640A1 (enExample) |
| HK (1) | HK1206267A1 (enExample) |
| IL (1) | IL200262A0 (enExample) |
| MX (1) | MX2009008488A (enExample) |
| RU (1) | RU2009133446A (enExample) |
| WO (1) | WO2008097661A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| WO2010120336A1 (en) * | 2009-04-15 | 2010-10-21 | Poniard Pharmaceuticals, Inc. | High bioavailability oral picoplatin anti-cancer therapy |
| AU2015263884B2 (en) * | 2014-05-23 | 2019-11-14 | Mingsight Pharmaceuticals, Inc. | Treatment of autoimmune disease |
| CN107778331B (zh) * | 2016-08-27 | 2020-06-30 | 鲁南制药集团股份有限公司 | 一种甲啶铂的提纯方法 |
| CN108864177B (zh) * | 2018-04-20 | 2020-07-28 | 公安部物证鉴定中心 | [2h3]-1-甲氨基-2-苯基丙烷的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9502799D0 (en) * | 1995-02-14 | 1995-04-05 | Johnson Matthey Plc | Improvements in platinum complexes |
| DE60032517T2 (de) * | 2000-02-16 | 2007-10-04 | Astellas Pharma Inc. | Heilmittel gegen durch endothelin verursachte erkrankungen |
| JP2004529929A (ja) * | 2001-04-23 | 2004-09-30 | ニュクリスト ファーマシューティカルズ コーポレーション | アポトーシスの誘導およびマトリックスメタロプロテイナーゼの阻害のための金属の使用 |
| DE10141528B4 (de) * | 2001-08-24 | 2006-08-10 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung |
| US20050119238A1 (en) * | 2002-03-01 | 2005-06-02 | Baron John A. | Compositions and methods for preventing sporadic neoplasia in colon |
| WO2004006859A2 (en) * | 2002-07-16 | 2004-01-22 | Sonus Pharmaceuticals, Inc. | Platinum compound |
| US20040101553A1 (en) * | 2002-08-02 | 2004-05-27 | Transave, Inc. | Platinum aggregates and process for producing the same |
| US20050249822A1 (en) * | 2004-03-18 | 2005-11-10 | Transave, Inc. | Administration of cisplatin by inhalation |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
-
2008
- 2008-02-08 CN CN201410283507.2A patent/CN104288119A/zh active Pending
- 2008-02-08 BR BRPI0806418-0A patent/BRPI0806418A2/pt not_active IP Right Cessation
- 2008-02-08 KR KR1020097018780A patent/KR20090109129A/ko not_active Withdrawn
- 2008-02-08 CN CN200880011357A patent/CN101678046A/zh active Pending
- 2008-02-08 JP JP2009549128A patent/JP2010518089A/ja active Pending
- 2008-02-08 CA CA002677640A patent/CA2677640A1/en not_active Abandoned
- 2008-02-08 RU RU2009133446/15A patent/RU2009133446A/ru not_active Application Discontinuation
- 2008-02-08 MX MX2009008488A patent/MX2009008488A/es not_active Application Discontinuation
- 2008-02-08 EP EP08725393A patent/EP2114418A4/en not_active Withdrawn
- 2008-02-08 AU AU2008214202A patent/AU2008214202A1/en not_active Abandoned
- 2008-02-08 WO PCT/US2008/001752 patent/WO2008097661A1/en not_active Ceased
-
2009
- 2009-08-06 IL IL200262A patent/IL200262A0/en unknown
-
2015
- 2015-07-21 HK HK15106959.9A patent/HK1206267A1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1555022B1 (en) | Sustained release formulation of acetaminophen and tramadol | |
| US7585520B2 (en) | Compositions containing both sedative and non-sedative antihistamines and sleep aids | |
| JP2010518089A5 (enExample) | ||
| JPH11501949A (ja) | プロトンポンプ抑制剤およびプロキネティック剤を含有する経口用医薬剤形 | |
| JP2000508673A (ja) | イバンドロネートを含む経口薬理製剤 | |
| MX2007010889A (es) | Formulaciones farmaceuticas gastrorresistentes que contienen rifaximina. | |
| KR20100119539A (ko) | 다이펜하이드라민을 포함하는 경구 분해성 정제 | |
| TW201838623A (zh) | 祛鐵斯若(deferasirox)之口服配方 | |
| CN113908153B (zh) | 一种布瓦西坦药物组合物、其制备方法及应用 | |
| CN109310642B (zh) | 美沙拉嗪的口服药物组合物 | |
| JP7064683B2 (ja) | 腸溶層破損防止用組成物 | |
| JP2010518088A5 (enExample) | ||
| JP2008519070A5 (enExample) | ||
| RU2009133446A (ru) | Стабилизированная дозированная форма пикоплатина для перорального применения | |
| JP5208729B2 (ja) | 徐放性錠剤の製造方法 | |
| JP2017122056A (ja) | 医薬含有造粒物の製造方法 | |
| JPH10139670A (ja) | インターロイキン１２誘導物質及び医薬組成物 | |
| HUP0303382A2 (hu) | Venlafaxin-hidroklorid-tartalmú pelletek | |
| JP2008519069A5 (enExample) | ||
| CN102920707A (zh) | 一种复方抗结核制剂的制备工艺 | |
| WO2009084216A1 (ja) | 経口粉粒状抗腫瘍剤 | |
| CN109152772A (zh) | 烟酰胺的口服药物组合物 | |
| CN105025883A (zh) | 右哌甲酯或其盐的调节释放的药物组合物 | |
| KR20140076998A (ko) | 에스오메프라졸 유리염기 또는 그의 알칼리염을 포함하는 고미가 차폐된 약학 제제 및 이의 제조방법 | |
| JP3592723B2 (ja) | 非崩壊・持続性カプセル製剤 |